Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (13757)
All Articles published online
|
Publishing Process of This Article
|
Aug 7, 2019 (publication date) through Dec 4, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | De Mattia E, Cecchin E, Guardascione M, Foltran L, Di Raimo T, Angelini F, D’Andrea M, Toffoli G. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. World J Gastroenterol 2019; 25(29): 3870-3896 [PMID: 31413525 DOI: 10.3748/wjg.v25.i29.3870] |
|---|---|
| URL: | https://www.wjgnet.com/2220-315x/full/v25/i29/3870.htm |
| Number | Citing Articles |
| 1 |
Zu‐Yau Lin, Ming‐Lun Yeh, Ching‐I Huang, Shinn‐Cherng Chen, Chung‐Feng Huang, Jee‐Fu Huang, Chia‐Yen Dai, Ming‐Lung Yu, Wan‐Long Chuang. Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression. The Kaohsiung Journal of Medical Sciences 2022; 38(2): 157 doi: 10.1002/kjm2.12471
|
| 2 |
QingTao Ni, Chi Pan, ShengBin Dai, Peng Wang. <p>Immunotherapy Combined with Chemotherapy as a Promising Therapy for a EGFR Exon 19 Deletion with MET Amplification Patient with Non-Small-Cell Lung Cancer: A Case Report</p>. OncoTargets and Therapy 2020; : 3039 doi: 10.2147/OTT.S243988
|
| 3 |
Yinghai Xie, Changwei Liu, Shuping Zhou, Qi Wang, Xiaolong Tang. Lupeol-Loaded Nanoparticles Enhance the Radiosensitivity of Hepatocellular Carcinoma by Inhibiting the Hyperactivation in Raf/Mitogen-Activated Protein Kinase and Phospatidylinositol-3 Kinase/mTOR Pathways. Journal of Biomedical Nanotechnology 2021; 17(11): 2247 doi: 10.1166/jbn.2021.3194
|
| 4 |
Ying Zhao, Guo-Sheng He, Gong Li. Triplet regimen as a novel modality for advanced unresectable hepatocellular carcinoma: A case report and review of literature. World Journal of Clinical Cases 2023; 11(27): 6558-6564 doi: 10.12998/wjcc.v11.i27.6558
Abstract(416) |
Core Tip(288) |
Full Article(HTML)(1115)
|
Full Article with Cover (PDF)-3163K(117)
|
Full Article (Word)-627K(12)
|
Audio-773K(4)
|
Peer-Review Report-208K(31)
|
Answering Reviewers-414K(28)
|
Full Article (PDF)-2865K(79)
|
Full Article (XML)-84K(28)
|
Times Cited (0)
|
Total Visits (3144)
|
Open
|
| 5 |
Mohammad K. Mohammad, Guoli Chen. Practical Oncologic Molecular Pathology. 2021; : 171 doi: 10.1007/978-3-030-73227-1_8
|
| 6 |
Zengbin Wang, Linqing Wu, Yu Zhou, Zhong Chen, Tao Zhang, Hong Wei, Zhihong Wang. Protein and metabolic profiles of tyrosine kinase inhibitors co-resistant liver cancer cells. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1394241
|
| 7 |
Giovanni Galati, Antonio Fabio Massimo Vainieri, Claudia Angela Maria Fulgenzi, Stefano Di Donato, Marianna Silletta, Paolo Gallo, Angelo Onorato, Umberto Vespasiani-Gentilucci, Antonio Picardi. Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. Current Drug Metabolism 2020; 21(11): 866 doi: 10.2174/1389200221999200918141239
|
| 8 |
A. Yu. Goryainova, A. I. Stukan, R. A. Murashko, S. V. Sharov, O. I. Kirsanova, E. V. Lymar. Efficacy of the immune checkpoint inhibitor nivolumab in the treatment of advanced hepatocellular carcinoma with the exhausted possibilities of therapy with tyrosine kinase inhibitors. Meditsinskiy sovet = Medical Council 2021; (20): 84 doi: 10.21518/2079-701X-2021-20-84-93
|
| 9 |
Zu-Yau Lin, Ming-Lun Yeh, Ching-I. Huang, Po-Cheng Liang, Po-Yao Hsu, Shinn-Cherng Chen, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Ming-Lung Yu, Wan-Long Chuang. Advantage of clinical colchicine concentration to promote sorafenib or regorafenib anti-cancer effects on hepatocellular carcinoma. Biomedicine & Pharmacotherapy 2022; 153: 113540 doi: 10.1016/j.biopha.2022.113540
|
| 10 |
Reyihanguli Aimaier, Haoran Li, Wenzhi Cao, Xiyuan Cao, Hui Zhang, Jia You, Jingjing Zhao, Qi Zhang, Li Yin, Qinshuang Mei, Xiaorong Zhang, Weiquan Wang, Huixin Zhao, Jinyu Li, Heping Zhao. The Secondary Metabolites of Bacillus subtilis Strain Z15 Induce Apoptosis in Hepatocellular Carcinoma Cells. Probiotics and Antimicrobial Proteins 2023; doi: 10.1007/s12602-023-10181-4
|
| 11 |
William A. Zammarrelli, Weining Ma, Kevin Espino, Sushmita Gordhandas, Effi Yeoshoua, Sarah Ehmann, Qin Zhou, Alexia Iasonos, Nadeem R. Abu-Rustum, Carol Aghajanian, Angela K. Green, Maria M. Rubinstein, Vicky Makker. Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer. Gynecologic Oncology 2023; 178: 27 doi: 10.1016/j.ygyno.2023.09.010
|
| 12 |
Dragica Pavlovic, Danijela Niciforovic, Dragana Papic, Katarina Milojevic, Marina Markovic. CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity – a narrative review. Therapeutic Advances in Medical Oncology 2023; 15 doi: 10.1177/17588359231205848
|
| 13 |
Qinglong Yang, Gang Wu. CircRNA-001241 mediates sorafenib resistance of hepatocellular carcinoma cells by sponging miR-21-5p and regulating TIMP3 expression. Gastroenterología y Hepatología (English Edition) 2022; 45(10): 742 doi: 10.1016/j.gastre.2021.11.004
|
| 14 |
Stefano Fogli, Giulia Gianfilippo, Federico Cucchiara, Marzia Del Re, Laura Valerio, Rossella Elisei, Romano Danesi. Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer. Critical Reviews in Oncology/Hematology 2021; 163: 103366 doi: 10.1016/j.critrevonc.2021.103366
|
| 15 |
Zhengbin Zhao, Jing Gao, Shuangsheng Huang. LncRNA SNHG7 Promotes the HCC Progression Through miR-122-5p/FOXK2 Axis. Digestive Diseases and Sciences 2022; 67(3): 925 doi: 10.1007/s10620-021-06918-2
|
| 16 |
Vahid Mansouri, Nima Beheshtizadeh, Maliheh Gharibshahian, Leila Sabouri, Mohammad Varzandeh, Nima Rezaei. Recent advances in regenerative medicine strategies for cancer treatment. Biomedicine & Pharmacotherapy 2021; 141: 111875 doi: 10.1016/j.biopha.2021.111875
|
| 17 |
Miaomiao Li, Juntao Hu, Riming Jin, Hongxia Cheng, Huaping Chen, Limin Li, Kun Guo. <p>Effects of LRP1B Regulated by HSF1 on Lipid Metabolism in Hepatocellular Carcinoma</p>. Journal of Hepatocellular Carcinoma 2020; : 361 doi: 10.2147/JHC.S279123
|
| 18 |
Wei Zhang, Hui-Fang Kong, Xu-Dong Gao, Zheng Dong, Ying Lu, Jia-Gan Huang, Hong Li, Yong-Ping Yang. Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma. World Journal of Gastroenterology 2020; 26(35): 5287-5301 doi: 10.3748/wjg.v26.i35.5287
|
| 19 |
Jianrong Zheng, Liao Zeng, Mingqing Tang, Hongjun Lin, Chao Pi, Ruian Xu, Xiuling Cui. Novel Ferrocene Derivatives Induce G0/G1 Cell Cycle Arrest and Apoptosis through the Mitochondrial Pathway in Human Hepatocellular Carcinoma. International Journal of Molecular Sciences 2021; 22(6): 3097 doi: 10.3390/ijms22063097
|
| 20 |
Yiran Chen, Li Li, Jie Lan, Yang Cui, Xiaosong Rao, Jing Zhao, Tao Xing, Gaoda Ju, Guangtao Song, Jizhong Lou, Jun Liang. CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma. Molecular Cancer 2022; 21(1) doi: 10.1186/s12943-021-01466-9
|
| 21 |
Hiroyuki Ogawa, Kosuke Kaji, Norihisa Nishimura, Hirotetsu Takagi, Koji Ishida, Hiroaki Takaya, Hideto Kawaratani, Kei Moriya, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji. Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis. Journal of Cellular and Molecular Medicine 2021; 25(8): 4001 doi: 10.1111/jcmm.16363
|
| 22 |
Wentao Bo, Yan Chen. Lenvatinib resistance mechanism and potential ways to conquer. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1153991
|
| 23 |
Yangjin Huang, Jun Xu, Chunming Xie, Yuejuan Liao, Rong Lin, Yuan Zeng, Fujun Yu. A Novel Gene Pair CSTF2/DPE2A Impacts Prognosis and Cell Cycle of Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 2023; : 1639 doi: 10.2147/JHC.S413935
|
| 24 |
Mengfei Han, Geliang Yang, Qing Lin, Yanlong Yang, Huiqing Zhang, Yonghua Su. Determination of Endogenous Bufalin in Serum of Patients With Hepatocellular Carcinoma Based on HPLC-MS/MS. Frontiers in Oncology 2020; 9 doi: 10.3389/fonc.2019.01572
|
| 25 |
Gabriele Perrone, Luigi Rigacci, Giandomenico Roviello, Ida Landini, Alberto Fabbri, Lorenzo Iovino, Benedetta Puccini, Emanuele Cencini, Enrico Orciuolo, Monica Bocchia, Alberto Bosi, Enrico Mini, Stefania Nobili. Validation of single nucleotide polymorphisms potentially related to R-CHOP resistance in diffuse large B-cell lymphoma patients. Cancer Drug Resistance 2024; doi: 10.20517/cdr.2024.10
|
| 26 |
Junjie Ao, Tetsuhiro Chiba, Shuhei Shibata, Akane Kurosugi, Na Qiang, Yaojia Ma, Motoyasu Kan, Terunao Iwanaga, Takafumi Sakuma, Hiroaki Kanzaki, Kengo Kanayama, Ryuta Kojima, Yuko Kusakabe, Masato Nakamura, Tomoko Saito, Ryo Nakagawa, Takayuki Kondo, Sadahisa Ogasawara, Eiichiro Suzuki, Ryosuke Muroyama, Jun Kato, Naoya Mimura, Tatsuo Kanda, Hitoshi Maruyama, Naoya Kato. Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications 2021; 549: 171 doi: 10.1016/j.bbrc.2021.02.097
|
| 27 |
Zu‐Yau Lin, Ming‐Lun Yeh, Ching‐I Huang, Shinn‐Cherng Chen, Chung‐Feng Huang, Jee‐Fu Huang, Chia‐Yen Dai, Ming‐Lung Yu, Wan‐Long Chuang. Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma. The Kaohsiung Journal of Medical Sciences 2021; 37(7): 616 doi: 10.1002/kjm2.12374
|
| 28 |
Li Du, Yichun Ji, Bing Xin, Jiemeng Zhang, Li-Chun Lu, Christopher K. Glass, Gen-Sheng Feng. Shp2 Deficiency in Kupffer Cells and Hepatocytes Aggravates Hepatocarcinogenesis by Recruiting Non-Kupffer Macrophages. Cellular and Molecular Gastroenterology and Hepatology 2023; 15(6): 1351 doi: 10.1016/j.jcmgh.2023.02.011
|
| 29 |
Ran You, Yanjun Yang, Guowen Yin, Hao Jiang, Yousheng Lu, Liang Gui, Jun Bao, Qingyu Xu, Liang Feng. CPEB2 Suppresses Hepatocellular Carcinoma Epithelial–Mesenchymal Transition and Metastasis through Regulating the HIF-1α/miR-210-3p/CPEB2 Axis. Pharmaceutics 2023; 15(7): 1887 doi: 10.3390/pharmaceutics15071887
|
| 30 |
Guangzhen Ma, Jirong Chen, Tiantian Wei, Jia Wang, Wenshan Chen. Inhibiting roles of FOXA2 in liver cancer cell migration and invasion by transcriptionally suppressing microRNA-103a-3p and activating the GREM2/LATS2/YAP axis. Cytotechnology 2021; 73(4): 523 doi: 10.1007/s10616-021-00475-2
|
| 31 |
Huili Lai, Liping Zhong, Yong Huang, Yongxiang Zhao, Zhiyong Qian. Progress in Application of Nanotechnology in Sorafenib. Journal of Biomedical Nanotechnology 2021; 17(4): 529 doi: 10.1166/jbn.2021.3061
|
| 32 |
Luca Bedon, Michele Dal Bo, Monica Mossenta, Davide Busato, Giuseppe Toffoli, Maurizio Polano. A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients. International Journal of Molecular Sciences 2021; 22(3): 1075 doi: 10.3390/ijms22031075
|
| 33 |
Nurbubu T. Moldogazieva, Sergey P. Zavadskiy, Susanna S. Sologova, Innokenty M. Mokhosoev, Alexander A. Terentiev. Predictive biomarkers for systemic therapy of hepatocellular carcinoma. Expert Review of Molecular Diagnostics 2021; 21(11): 1147 doi: 10.1080/14737159.2021.1987217
|
| 34 |
Gül KOCA, Sakou SEYDOU, Özlem YILDIRIM. Kanser immünoterapisinde güncel yaklaşımlar ve immünoterapinin sınırlayıcı etkilerine genel bakış. Turkish Journal of Clinics and Laboratory 2022; 13(1): 153 doi: 10.18663/tjcl.1038881
|
| 35 |
Sara Armani, Andreas Geier, Thomas Forst, Uta Merle, David H. Alpers, Martin W. Lunnon. Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug–drug interactions. British Journal of Clinical Pharmacology 2024; 90(4): 942 doi: 10.1111/bcp.15990
|
| 36 |
Gloria Ravegnini, Giorgia Valori, Qianqian Zhang, Riccardo Ricci, Patrizia Hrelia, Sabrina Angelini. Pharmacogenetics in the treatment of gastrointestinal stromal tumors – an updated review. Expert Opinion on Drug Metabolism & Toxicology 2020; 16(9): 797 doi: 10.1080/17425255.2020.1789589
|
| 37 |
Yiyin Chen, Banglun Pan, Jiacheng Qiu, Zhanfei Chen, Xiaoqian Wang, Nanhong Tang. Increased effects of 2,5-dimethylcelecoxib on sensitivity of hepatocellular carcinoma cells to sorafenib via CYP3A5 expression and activation of AMPK. Toxicology in Vitro 2021; 76: 105226 doi: 10.1016/j.tiv.2021.105226
|
| 38 |
Miao Li, Tingting Tan, Yu Geng, Yue Tao, Jie Pan, Jun Zhang, Qin Xu, Han Shen, Lingyun Zuo, Yuxin Chen. HOXB13 facilitates hepatocellular carcinoma progression by activating AKT/mTOR signaling pathway. Annals of Hepatology 2023; 28(1): 100759 doi: 10.1016/j.aohep.2022.100759
|
| 39 |
Silvia Mezzalira, Elena De Mattia, Michela Guardascione, Chiara Dalle Fratte, Erika Cecchin, Giuseppe Toffoli. Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients’ Management and Therapy Outcomes. International Journal of Molecular Sciences 2019; 20(21): 5498 doi: 10.3390/ijms20215498
|
| 40 |
Julia C. F. Quintanilha, Kelli Hammond, Yingmiao Liu, Federica Marmorino, Beatrice Borelli, Chiara Cremolini, Andrew B. Nixon, Federico Innocenti. Plasma levels of VEGF‐A and VCAM‐1 as predictors of drug‐induced hypertension in patients treated with VEGF pathway inhibitors. British Journal of Clinical Pharmacology 2022; 88(9): 4171 doi: 10.1111/bcp.15356
|
| 41 |
Elisa Callegari, Paola Guerriero, Cristian Bassi, Lucilla D’Abundo, Antonio Frassoldati, Edi Simoni, Laura Astolfi, Enrico Maria Silini, Silvia Sabbioni, Massimo Negrini. miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models. Molecular Therapy - Nucleic Acids 2022; 29: 538 doi: 10.1016/j.omtn.2022.07.015
|
| 42 |
Antoni Sureda, Miquel Martorell, Xavier Capó, Margalida Monserrat-Mesquida, Maria Magdalena Quetglas-Llabrés, Mahsa Rasekhian, Seyed M. Nabavi, Silvia Tejada. Antitumor Effects of Triterpenes in Hepatocellular Carcinoma. Current Medicinal Chemistry 2021; 28(13): 2465 doi: 10.2174/0929867327666200602132000
|
| 43 |
Wenzhen Li, Yifan Wang, Xinbo Zhou, Xiaohong Pan, Junhong Lü, Hongliu Sun, Zeping Xie, Shayan Chen, Xue Gao. The anti-tumor efficacy of 20(S)-protopanaxadiol, an active metabolite of ginseng, according to fasting on hepatocellular carcinoma. Journal of Ginseng Research 2022; 46(1): 167 doi: 10.1016/j.jgr.2021.06.002
|
| 44 |
Zhijia Sun, Chunyuan Xue, Jiangbo Li, Hui Zhao, Yimeng Du, Nan Du. LINC00244 suppresses cell growth and metastasis in hepatocellular carcinoma by downregulating programmed cell death ligand 1. Bioengineered 2022; 13(3): 7635 doi: 10.1080/21655979.2022.2050073
|
| 45 |
Fu He, Kangjian Song, Ge Guan, Junyu Huo, Yang Xin, Tianxiang Li, Chao Liu, Qingwei Zhu, Ning Fan, Yuan Guo, Liqun Wu. The Phenomenon of Gene Rearrangement is Frequently Associated with TP53 Mutations and Poor Disease-Free Survival in Hepatocellular Carcinoma. Pharmacogenomics and Personalized Medicine 2021; : 723 doi: 10.2147/PGPM.S313848
|
| 46 |
Tatjana Zekić, Mirjana Stanić Benić. Anti-programmed death-1 inhibitor nivolumab-induced immune-related adverse events: hepatitis, renal insufficiency, myositis, vitiligo, and hypothyroidism: a case-based review. Rheumatology International 2022; 43(3): 559 doi: 10.1007/s00296-022-05247-5
|
| 47 |
Marhaba Nurmamat, Haili Yan, Ru Wang, Huixin Zhao, Yanhong Li, Xiaojing Wang, Kaidirye Nurmaimaiti, Tamasha Kurmanjiang, Difang Luo, Jumagul Baodi, Guancheng Xu, Jinyu Li. Novel Copper(II) Complex with a 4-Acylpyrazolone Derivative and Coligand Induce Apoptosis in Liver Cancer Cells. ACS Medicinal Chemistry Letters 2021; 12(3): 467 doi: 10.1021/acsmedchemlett.0c00680
|
| 48 |
Rui Zhang, Wei-Jia Mo, Lan-Shan Huang, Ji-Tian Chen, Wei-Zi Wu, Wei-Ying He, Zhen-Bo Feng. Identifying the Prognostic Risk Factors of Synaptojanin 2 and Its Underlying Perturbations Pathways in Hepatocellular Carcinoma. Bioengineered 2021; 12(1): 855 doi: 10.1080/21655979.2021.1890399
|
| 49 |
Yan-Fei Li, Fang-Yuan Zheng, Xin-Yu Miao, Hai-Long Liu, Yao-Yao Zhang, Nai-Xia Chao, Fa-Rong Mo. Cell division cyclin 25C knockdown inhibits hepatocellular carcinoma development by inducing endoplasmic reticulum stress. World Journal of Gastroenterology 2024; 30(19): 2564-2574 doi: 10.3748/wjg.v30.i19.2564
|
| 50 |
Linjun Liang, Xiaoyan Wang, Shuying Huang, Yanwei Chen, Peng Zhang, Liang Li, Yong Cui. Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1046771
|
| 51 |
Xiaoqin Lv, Xia Xiang, Yue Wu, Yang Liu, Ruqing Xu, Qin Xiang, Guoqi Lai. GATA binding protein 4 promotes the expression and transcription of hepatitis B virus by facilitating hepatocyte nuclear factor 4 alpha in vitro. Virology Journal 2021; 18(1) doi: 10.1186/s12985-021-01668-z
|
| 52 |
Yue Hu, Min Zhou, Jing Tang, Shuang Li, Hongli Liu, Jianli Hu, Hong Ma, Junli Liu, Tingting Qin, Xiongjie Yu, Yongshun Chen, Jin Peng, Yanmei Zou, Tao Zhang, Jun Xue. Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Clinical Cancer Research 2023; 29(20): 4088 doi: 10.1158/1078-0432.CCR-22-2592
|
| 53 |
Yu-Jie Xu, Zhi-Cheng Lai, Anna Kan, Hui Liu, Yu Huang, Yue-Yuan Lai, Jie-Feng Weng, Zhao-Feng Wu, Ming Shi, Wei-Li Gu, Shuai Zhang, Min-Ke He. TMB Signature-Related RCAN2 Promotes Apoptosis by Upregulating EHF/DR5 Pathway in Hepatocellular Carcinoma. Frontiers in Bioscience-Landmark 2024; 29(7) doi: 10.31083/j.fbl2907243
|
| 54 |
Jose J.G. Marin, Rocio I.R. Macias, Maria J. Monte, Marta R. Romero, Maitane Asensio, Anabel Sanchez-Martin, Candela Cives-Losada, Alvaro G. Temprano, Ricardo Espinosa-Escudero, Maria Reviejo, Laura H. Bohorquez, Oscar Briz. Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. Cancers 2020; 12(6): 1663 doi: 10.3390/cancers12061663
|
| 55 |
Raffaele Borriello, Lucia Cerrito, Antonio Gasbarrini, Francesca Romana Ponziani. Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview. Expert Opinion on Drug Metabolism & Toxicology 2023; 19(11): 785 doi: 10.1080/17425255.2023.2272598
|
| 56 |
Xuan-Yu Gu, Jin-Long Huo, Zhi-Yong Yu, Ji-Chang Jiang, Ya-Xuan Xu, Li-Jin Zhao. Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects. Oncologie 2024; 26(1): 9 doi: 10.1515/oncologie-2023-0412
|
| 57 |
Federico Piñero, Marcos Thompson, Juan Ignacio Marín, Marcelo Silva. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?. World Journal of Transplantation 2020; 10(11): 297-306 doi: 10.5500/wjt.v10.i11.297
|
| 58 |
Julia C. F. Quintanilha, Susan Geyer, Amy S. Etheridge, Alessandro Racioppi, Kelli Hammond, Daniel J. Crona, Carol E. Peña, Sawyer B. Jacobson, Federica Marmorino, Daniele Rossini, Chiara Cremolini, Hanna K. Sanoff, Ghassan K. Abou-Alfa, Federico Innocenti. KDR genetic predictor of toxicities induced by sorafenib and regorafenib. The Pharmacogenomics Journal 2022; 22(5-6): 251 doi: 10.1038/s41397-022-00279-3
|
| 59 |
Michele Dal Bo, Elena De Mattia, Lorena Baboci, Silvia Mezzalira, Erika Cecchin, Yehuda G. Assaraf, Giuseppe Toffoli. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates 2020; 51: 100702 doi: 10.1016/j.drup.2020.100702
|
| 60 |
Ying Jia, Yufei Xing, Meitian Yang, Muhammad Wasim Khan. Efficacy of Sorafenib Combined with Interventional Therapy on Primary Liver Cancer Patients and Its Effect on Serum AFP, VEGF, and GGT. Journal of Oncology 2021; 2021: 1 doi: 10.1155/2021/9120265
|
| 61 |
Qinglong Yang, Gang Wu. CircRNA-001241 mediates sorafenib resistance of hepatocellular carcinoma cells by sponging miR-21-5p and regulating TIMP3 expression. Gastroenterología y Hepatología 2022; 45(10): 742 doi: 10.1016/j.gastrohep.2021.11.007
|
| 62 |
John R. Bergquist, Amy Y. Li, Christopher S. Javadi, Byrne Lee, Jeffrey A. Norton, George A. Poultsides, Monica M. Dua, Brendan C. Visser. Regional lymph node sampling in hepatoma resection: insight into prognosis. HPB 2021; 23(9): 1360 doi: 10.1016/j.hpb.2021.01.006
|
| 63 |
Ewa Wolinska, Maciej Skrzypczak. Epigenetic Changes Affecting the Development of Hepatocellular Carcinoma. Cancers 2021; 13(16): 4237 doi: 10.3390/cancers13164237
|
| 64 |
Roland Sonntag, Christian Penners, Marlene Kohlhepp, Ute Haas, Daniela Lambertz, Andreas Kroh, Thorsten Cramer, Fabio Ticconi, Ivan G. Costa, Frank Tacke, Nikolaus Gassler, Christian Trautwein, Christian Liedtke. Cyclin E1 in Murine and Human Liver Cancer: A Promising Target for Therapeutic Intervention during Tumour Progression. Cancers 2021; 13(22): 5680 doi: 10.3390/cancers13225680
|
| 65 |
Xinyao Hu, Hua Zhu, Yang Shen, Xiaoyu Zhang, Xiaoqin He, Ximing Xu. The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.696705
|
| 66 |
Renske Altena, Svetlana Bajalica-Lagercrantz, Andri Papakonstantinou. Pharmacogenomics for Prediction of Cardiovascular Toxicity: Landscape of Emerging Data in Breast Cancer Therapies. Cancers 2022; 14(19): 4665 doi: 10.3390/cancers14194665
|